FK506 + GP11046 + GP11511

This is a combination drug consisting of three investigational agents: **FK506** (tacrolimus), **GP11046**, and **GP11511**. - **Tacrolimus (FK506)** is a well-established immunosuppressant drug, primarily used to prevent organ rejection after transplantation. It is a macrolide calcineurin inhibitor that exerts its effects by binding to the immunophilin FKBP12, forming a complex that inhibits calcineurin. This inhibits T-cell activation through decreased production of interleukin-2 and other cytokines[1][3][4][6]. - **GP11046** and **GP11511** do not correspond to any widely recognized pharmaceutical agents in current publicly available literature or regulatory databases as of July 2025, and their mechanisms or properties are unknown. It is possible they are experimental code names for novel compounds. - As a combination, the drug is likely intended for immunosuppression or modulation of immune or inflammatory pathways, with FK506 as the known active component.

Other names

FK506 + GP11046 + GP11511